�MicroIslet Inc. (OTCBB: MIIS), a biotech company in use in the development and commercialization of cell therapies for diabetes, is pleased to reputation on the Company's presentment at the XXII International Congress Of The Transplantation Society Meeting, being held August 10-14, 2008, at the Sydney Convention & Exhibition Centre in Sydney, Australia. Drs. Ingrid Stuiver and Amaresh Basu, MicroIslet's Senior Director and Vice President of R&D, severally, discussed the Company's developmental advances at the globular transplantation meeting.
MicroIslet's presentation outlined the extensive amount of presymptomatic data the Company has complied o'er the last-place few geezerhood. In compact, MicroIslet has tested MicroIslet-P�, the Company's lead ware candidate, in hundreds of rodents and has lately completed a trial with nineteen nonhuman primates, some of which received up to trine separate transplant procedures. The numerous transplantations of MicroIslet-P�resulted in no observed base hit issues, while producing significant improvements in blood glucose levels.
"MicroIslet presented information in Sydney that demonstrated that our lead production candidate, MicroIslet-P, was a safe and effective treatment in rodents and order Primates that had been rendered diabetic," said Dr. Stuiver. "Over the last geezerhood, our preclinical testing of MicroIslet-P has been extensive and thorough. We are proud of our results and late developmental progression, and remain on butt for human dosing in the fourth quarter of 2008."
Dr. Amaresh Basu added, "The response and feedback we received from the conference participants in Sydney was very encouraging. We were quite pleased to share our advances with such a respected group of our comrade researchers and industry peers. With our preclinical programs now nearly complete, MicroIslet-P is self-collected to act into human clinical testing."
About MicroIslet, Inc.
MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of cell therapy for patients with insulin-dependent diabetes. MicroIslet has licensed several technologies from Duke University for isolation, culturing, storage, and microencapsulation of insulin-producing islet cells from porcine sources. The Company believes that these technologies, and other proprietary methods developed in-house, are substantial advances in the field of cellular therapeutics. MicroIslet is planning human clinical trials in the U.S., and exploring possible trials abroad. MicroIslet's ultimate goal is to offer jail cell transplantation therapies for diabetic patients general.
The Company's lead product, MicroIslet-PTM, consists of microencapsulated porcine islets for implantation into the abdominal cavity using a minimally invasive procedure. Microencapsulation involves circumferent islet cells with formulations of a highly biocompatible, ultra-pure biopolymer, called alginate, or other similar biocompatible polymers. The alginate coat allows insulin, glucose, oxygen and other nutrients to diffuse freely, while block antibodies and reducing the patient's immune response to the ingrained islet cells. It is hoped that MicroIslet-PTM will provide physiological and self-acting blood glucose control, thus reducing the need for insulin injections or infusions and constant blood glucose monitoring. The long term complications associated with type 1 diabetes, such as peripheral neuropathies, heart and kidney disease, and skin disorders, english hawthorn be mitigated by the tighter blood glucose control that would result from such a product.
Additional information close to MicroIslet keister be constitute at hTTP://www.microislet.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press handout are advanced statements within the signification of the "Safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These innovative statements ar subject to risks and uncertainties that may cause actual results to differ materially, including MicroIslet's on the job capital deficit, which includes a substantial amount of indebtedness which is full-blown and imputable on demand; MicroIslet's need to raise substantial extra funds in order to fund its development design and continue as a going worry; the risks and uncertainties inherent in medical discourse discovery; development and commercialization; the risks and uncertainties associated with MicroIslet's early stage xenotransplant technologies; the risks and uncertainties of governmental approvals and regulation, including extraneous government approvals for clinical trials external the United States; dependency on a sole source supplier of animal parts and a sole source manufacturer of encapsulated islets for presymptomatic and clinical studies; the risks that MicroIslet's competitors will develop or market technologies or products that are more than effective or commercially attractive than MicroIslet's products; and other risks detailed from time to time in MicroIslet's near recent filings with the Securities and Exchange Commission. These advanced statements talk only as of the date hereof. MicroIslet disclaims any spirit or indebtedness to update these modern statements.
More info
Friday 22 August 2008
Tuesday 12 August 2008
Number Of Tuberculosis Cases Among Foreign-Born Residents In North Carolina Increasing
�
While the number of cases of tuberculosis among North Carolina residents has declined over the last two decades, cases among foreign-born residents are increasing, the Raleigh News & Observer reports. Foreign-born residents account for more than 40% of the state's cases, and the number is increasing as the foreign universe grows, according to the News & Observer. In 2000, 26% of the state's cases were among foreign-born residents compared with less than 3% in 1983. Meanwhile, the number of cases among non-immigrants in the state is declining, according to Jeff Engel, a North Carolina epidemiologist.
Nationwide, 57% of TB cases in 2006 were among foreign-born residents, and between 1993 and 2006, the number of cases among foreign-born residents increased by 5%. The number of cases among the rest of the U.S. population declined by 66% from 1993 to 2006, according to the News & Observer. "If we continue on this trend, it's going to be a big problem," Maureen O'Rourke, TB program coach at the state Division of Public Health, aforesaid.
A recent CDC study found that about 30% of immigrants in the U.S. -- including students, migrant workers, visitors and undocumented immigrants -- ingest never been tested for the disease, which is treatable with antibiotics. Public health officials contend that increased screening and treatment for the disease could stop the spread. However, the state has limited resources useable to treat thousands of new patients, and under federal legal philosophy those without health insurance are eligible for no-cost care. Engel said he would like to begin an consciousness campaign encouraging immigrants to be screened for the disease but it would require more than federal financing. "I call back it's a major concern," Engel said, adding, "A national business" (Collins, Raleigh News & Observer, 8/6).
Reprinted with kind permission from http://www.kaisernetwork.org. You canful view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for electronic mail delivery at http://www.kaisernetwork.
While the number of cases of tuberculosis among North Carolina residents has declined over the last two decades, cases among foreign-born residents are increasing, the Raleigh News & Observer reports. Foreign-born residents account for more than 40% of the state's cases, and the number is increasing as the foreign universe grows, according to the News & Observer. In 2000, 26% of the state's cases were among foreign-born residents compared with less than 3% in 1983. Meanwhile, the number of cases among non-immigrants in the state is declining, according to Jeff Engel, a North Carolina epidemiologist.
Nationwide, 57% of TB cases in 2006 were among foreign-born residents, and between 1993 and 2006, the number of cases among foreign-born residents increased by 5%. The number of cases among the rest of the U.S. population declined by 66% from 1993 to 2006, according to the News & Observer. "If we continue on this trend, it's going to be a big problem," Maureen O'Rourke, TB program coach at the state Division of Public Health, aforesaid.
A recent CDC study found that about 30% of immigrants in the U.S. -- including students, migrant workers, visitors and undocumented immigrants -- ingest never been tested for the disease, which is treatable with antibiotics. Public health officials contend that increased screening and treatment for the disease could stop the spread. However, the state has limited resources useable to treat thousands of new patients, and under federal legal philosophy those without health insurance are eligible for no-cost care. Engel said he would like to begin an consciousness campaign encouraging immigrants to be screened for the disease but it would require more than federal financing. "I call back it's a major concern," Engel said, adding, "A national business" (Collins, Raleigh News & Observer, 8/6).
Reprinted with kind permission from http://www.kaisernetwork.org. You canful view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for electronic mail delivery at http://www.kaisernetwork.
Wednesday 6 August 2008
Erosion
Artist: Erosion
Genre(s):
Metal: Thrash
Discography:
Mortal Agony
Year: 1988
Tracks: 10
Over the line of four albums and unitary EP released betwixt 1989 and 1995, Germany's Erosion always seemed like reluctant thrashers whose hearts actually belonged to hard-core. Led by utterer Chris Zenk, guitar player Stefan Römhild, drummer Klaus Nowakowski, and supported by a Spinal Tap-sized parade of henchmen (including, at one prison term, Paragon bassist Jan Bünning and future Holy Moses guitar player Michael Hankel), it was by chance this want of nidus that compromised the band's chances of success. By the firing of 1995's swan birdcall, Down, Daniel Geiger had stepped in for the foregone Zenk, only not for foresighted, as Erosion decided to break up a short time by and by.
Stars, Skin, Scandal: Secrets of Us Weekly
Roberto Vecchioni
Artist: Roberto Vecchioni
Genre(s):
Pop
Folk
Rock
Other
Easy Listening
Discography:
Il Contastorie
Year: 2005
Tracks: 16
Rotary Club of Malindi
Year: 2004
Tracks: 11
Le Ballate: Best of Roberto Vecchioni
Year: 2002
Tracks: 17
Il Lanciatore Di Coltelli
Year: 2002
Tracks: 10
Sogna Ragazzo Sogna
Year: 1999
Tracks: 10
Raccolta, CD 2
Year: 1997
Tracks: 15
El Bandolero Stanco
Year: 1997
Tracks: 10
Il Cielo Capovolto
Year: 1995
Tracks: 10
Blumun
Year: 1993
Tracks: 11
Camper, CD2
Year: 1992
Tracks: 10
Camper, CD1
Year: 1992
Tracks: 10
Per Amore Mio
Year: 1991
Tracks: 10
Il Capolavoro
Year: 1991
Tracks: 13
Milady
Year: 1989
Tracks: 8
Ippopotami
Year: 1986
Tracks: 11
Bei Tempi
Year: 1985
Tracks: 10
Hollywood, Hollywood
Year: 1982
Tracks: 8
Montecristo
Year: 1980
Tracks: 9
Luci a San Siro: Best of Roberto Vecchioni
Year: 1980
Tracks: 15
Robinson, come salvarsi La Vita
Year: 1979
Tracks: 10
Calabuig, Stranamore Ed Altri Incident
Year: 1978
Tracks: 8
Samarcanda
Year: 1977
Tracks: 6
Elisir
Year: 1976
Tracks: 10
Ipertensione
Year: 1975
Tracks: 7
Barbapapa
Year: 1975
Tracks: 9
L'uomo che si gioca il cielo a dadi
Year: 1973
Tracks: 10
Il Re Non Si Diverte
Year: 1973
Tracks: 8
Saldi Di Fine Stag
Year: 1972
Tracks: 8
Parabola
Year: 1971
Tracks: 10
Varie e Duetti
Year:
Tracks: 4
Il Grande Sogno
Year:
Tracks: 15
After graduating in 1968 from Milan's Catholic University, Italian singer/songwriter Roberto Vecchioni started sharing his rage for precept and music. After typography for outstanding local numbers racket, the creative person decided to start his solo calling in 1971, recording Parobola, which was released that same year. Saldi Di Fine Stagione followed in 1972 and L'uomo Che Si Gioca Il Cielo A Dadi in 1973; Vecchioni received an plunder from the local transcription critics association a class after. Roberto Vecchioni's breakthrough came in 1977 with "Samarcanda," his beginning bang up. In 1983, the gifted composer promulgated a book of verse and lyrics called Grande Sogno (The Great Dream).
Letters to Cleo
Subscribe to:
Posts (Atom)